Key Points
- Director Louis Sullivan sold 5,950 shares of United Therapeutics on Dec. 22 at an average price of $512.13, for a total of $3,047,173.50, according to an SEC filing.
- The company reported quarterly EPS of $7.16 (vs. $6.89 consensus) with $799.5M revenue, a 40.65% net margin, a market cap of about $21.98B and a P/E of 19.34; the stock’s 1‑year high is $519.99.
- Analysts’ consensus is a “Moderate Buy” with an average target of $505.00 (eight Buys, three Holds).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 50 shares of the firm's stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total transaction of $25,606.00. Following the transaction, the director owned 420 shares of the company's stock, valued at $215,090.40. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Jan Malcolm also recently made the following trade(s):
- On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $482.98, for a total transaction of $24,149.00.
United Therapeutics Price Performance
Shares of UTHR opened at $510.44 on Wednesday. The firm has a 50 day simple moving average of $466.64 and a 200-day simple moving average of $384.02. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The stock has a market cap of $21.98 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 5.10 and a beta of 0.86.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics's revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.39 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Analysts Set New Price Targets
UTHR has been the subject of a number of analyst reports. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Jefferies Financial Group reiterated a "buy" rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. Finally, Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $505.00.
Check Out Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Large investors have recently bought and sold shares of the company. CWM LLC lifted its stake in shares of United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company's stock worth $1,492,000 after acquiring an additional 3,487 shares in the last quarter. AXQ Capital LP increased its holdings in United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company's stock worth $1,117,000 after purchasing an additional 3,235 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company's stock valued at $14,027,000 after purchasing an additional 33,662 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company's stock worth $1,792,000 after buying an additional 2,655 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in United Therapeutics by 17.0% during the second quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company's stock valued at $5,612,000 after buying an additional 2,840 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
